CONNECT WITH US
HealthTech

HealthTech

Oura sues rival Ultrahuman again, threatening its U.S. smart ring comeback

TechCrunch — Biotech & Health logo

Published on

Add as a preferred source on Google
Oura sues rival Ultrahuman again, threatening its U.S. smart ring comeback

Smart ring maker Oura has sued Indian rival Ultrahuman again, seeking to block U.S. sales of its Ring Pro (pictured above) just months after the redesign helped the Bengaluru-based startup return to the American market following an import ban. The case is the latest in a string of patent disputes Oura has brought against competing smart-ring makers, including Samsung and RingConn.

In a complaint filed Thursday in a federal court in Texas, Oura alleged that Ultrahuman’s Ring Pro infringes two of its patents covering the ring’s design and internal components, including its battery and sensors. Oura is seeking monetary damages and a permanent injunction that would stop Ultrahuman from selling the ring.

Ultrahuman’s redesigned Ring Pro, launched in February, received a favorable ruling from U.S. Customs and Border Protection in March, paving the way for the startup’s return to the U.S. market. The decision followed an import ban on Ultrahuman’s earlier Ring Air, which took effect after Oura secured a patent infringement ruling from the International Trade Commission in August last year.

“Ultrahuman has a history of copying Oura’s innovations, as demonstrated by the 2025 ITC ruling against the company,” an Oura spokesperson said in a statement to TechCrunch. “Ultrahuman introduced a redesigned ring but failed to address continued infringement of Oura’s patents, seeking instead to capitalize on our innovation and the market leadership we have built.”

Oura argues that the Customs ruling covered only the patent involved in the earlier dispute, not the two patents cited in its latest lawsuit: D804,471 and 12,769,363.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.